Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

fludarabine phosphate 19Cyclophosphamide 18Tacrolimus 17Peripheral Blood Stem Cell Transplantation 17Mycophenolic Acid 17Antilymphocyte Serum 14Busulfan 13Whole-Body Irradiation 12Methotrexate 11Cyclosporine 11Melphalan 7mogamulizumab 6Methylprednisolone 6Etoposide 6Bexarotene 6Sirolimus 5Radiotherapy 5Flow Cytometry 5Filgrastim 5sargramostim 4pembrolizumab 4Vorinostat 4Transplantation 4Therapeutics 4Rituximab 4Lenalidomide 4Brentuximab Vedotin 4Alemtuzumab 4thymoglobulin 3romidepsin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Cutaneous × tislelizumab × Clear all
NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

BeiGene

Phase 2 Completed
77 enrolled 20 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡